{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:03:59Z","timestamp":1787965439146,"version":"build-2784847793"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFC2501704"],"award-info":[{"award-number":["2021YFC2501704"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-C&T-B-007"],"award-info":[{"award-number":["2021-I2M-C&T-B-007"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-051"],"award-info":[{"award-number":["2021-I2M-1-051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Hypophosphatasia (HPP) is a rare inherited disorder caused by <jats:italic>ALPL<\/jats:italic> gene mutations, with fracture nonunion being a serious complication. This study investigated the effects of teriparatide and asfotase alfa (AA) on femoral fracture healing of an adult patient with HPP, accompanied with a literature review.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A 37-year-old woman wheelchair-bound was diagnosed with HPP due to an extremely low serum alkaline phosphatase (ALP) level (4\u201310 U\/L), who suffered from bilateral femur pain and non-union of femoral shaft fractures on both sides. Compound heterozygous missense mutations (c.382G\u2009&gt;\u2009A and c.461C\u2009&gt;\u2009T) were identified in exon5 of <jats:italic>ALPL<\/jats:italic> gene. The patient received teriparatide sequential AA therapy. Serum levels of ALP, \u03b2-isomerized carboxy-telopeptide of type I collagen (\u03b2-CTX) and procollagen type 1 amino-terminal peptide (P1NP), bone mineral density (BMD) and skeletal X-ray were measured during the treatment. Literature was searched by keywords of \u201cHypophosphatasia\u201d, \u201cHPP\u201d, \u201cALPL\u201d, \u201cTNSALP\u201d, \u201cALP\u201d combined with \u201cAsfotase alfa\u201d, \u201cAA\u201d, \u201cenzyme replacement therapy\u201d, and \u201cERT\u201d.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>After unsuccessful 6-month teriparatide treatment for femoral fracture, AA treatment was initiated, at a dose of 2\u00a0mg\/kg, 3 times a week. After the first month of AA treatment, serum ALP level increased from 4 to 9206 U\/L, and serum calcium and phosphate levels decreased, with increase in PTH, \u03b2-CTX, and P1NP levels. After 4\u00a0months of AA treatment, her bone pain significantly alleviated, accompanied by significant shortening of the fracture line. After 10\u00a0months of AA therapy, the fracture demonstrated complete healing and the patient could walk independently. BMD at lumbar spine and hips was significantly increased. Among 295 adult patients with HPP reported in the literature, 213 (72.2%) exhibited skeletal-related symptoms and 91 (30.8%) presented with bone fractures. In addition to skeletal manifestations, the patients presented with early tooth loss, muscle weakness and ectopic calcification. AA treatment, spanning 9\u00a0weeks to 3\u00a0years, has been shown to increase ALP levels, promote fracture healing, improve mobility, and alleviate bone pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Adult HPP patients mainly present with recurrent or poorly healing fractures, bone pain, and early loss of teeth. AA replacement therapy can effectively promote fracture healing, relieve bone pain, and enhance mobility.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03663-x","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T21:49:31Z","timestamp":1743976171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of asfotase alfa on fracture healing of adult patient with hypophosphatasia and literature review"],"prefix":"10.1186","volume":"20","author":[{"given":"Songqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7270-4902","authenticated-orcid":false,"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,6]]},"reference":[{"key":"3663_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094303","author":"JM Villa-Suarez","year":"2021","unstructured":"Villa-Suarez JM, Garcia-Fontana C, Andujar-Vera F, et al. Hypophosphatasia: a unique disorder of bone mineralization. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22094303.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3663_CR2","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1038\/s41467-023-39833-3","volume":"14","author":"Y Yu","year":"2023","unstructured":"Yu Y, Rong K, Yao D, et al. The structural pathology for hypophosphatasia caused by malfunctional tissue non-specific alkaline phosphatase. Nat Commun. 2023;14(1):4048. https:\/\/doi.org\/10.1038\/s41467-023-39833-3.","journal-title":"Nat Commun"},{"issue":"4","key":"3663_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte MP. Hypophosphatasia: aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016;12(4):233\u201346. https:\/\/doi.org\/10.1038\/nrendo.2016.14.","journal-title":"Nat Rev Endocrinol"},{"key":"3663_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.metabol.2017.08.013","volume":"82","author":"E Mornet","year":"2018","unstructured":"Mornet E. Hypophosphatasia. Metabolism. 2018;82:142\u201355. https:\/\/doi.org\/10.1016\/j.metabol.2017.08.013.","journal-title":"Metabolism"},{"key":"3663_CR5","doi-asserted-by":"publisher","first-page":"1138599","DOI":"10.3389\/fendo.2023.1138599","volume":"14","author":"KM Dahir","year":"2023","unstructured":"Dahir KM, Kishnani PS, Martos-Moreno GA, et al. Impact of muscular symptoms and\/or pain on disease characteristics, disability, and quality of life in adult patients with hypophosphatasia: a cross-sectional analysis from the Global HPP Registry. Front Endocrinol (Lausanne). 2023;14:1138599. https:\/\/doi.org\/10.3389\/fendo.2023.1138599.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"3663_CR6","doi-asserted-by":"publisher","first-page":"e85971","DOI":"10.1172\/jci.insight.85971","volume":"1","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, Madson KL, Phillips D, et al. Asfotase alfa therapy for children with hypophosphatasia. JCI Insight. 2016;1(9):e85971. https:\/\/doi.org\/10.1172\/jci.insight.85971.","journal-title":"JCI Insight."},{"issue":"1","key":"3663_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.afos.2024.03.002","volume":"10","author":"D Inoue","year":"2024","unstructured":"Inoue D. Diagnosis and treatment of adult hypophosphatasia: Still a big challenge? Osteoporos Sarcopenia. 2024;10(1):1\u20132. https:\/\/doi.org\/10.1016\/j.afos.2024.03.002.","journal-title":"Osteoporos Sarcopenia"},{"issue":"2","key":"3663_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.11138\/ccmbm\/2017.14.1.230","volume":"14","author":"F Conti","year":"2017","unstructured":"Conti F, Ciullini L, Pugliese G. Hypophosphatasia: clinical manifestation and burden of disease in adult patients. Clin Cases Miner Bone Metab. 2017;14(2):230\u20134. https:\/\/doi.org\/10.11138\/ccmbm\/2017.14.1.230.","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"3","key":"3663_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00198-023-06844-1","volume":"35","author":"AA Khan","year":"2024","unstructured":"Khan AA, Brandi ML, Rush ET, et al. Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. Osteoporos Int. 2024;35(3):431\u20138. https:\/\/doi.org\/10.1007\/s00198-023-06844-1.","journal-title":"Osteoporos Int"},{"issue":"1\u20132","key":"3663_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2017.07.010","volume":"122","author":"PS Kishnani","year":"2017","unstructured":"Kishnani PS, Rush ET, Arundel P, et al. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2017;122(1\u20132):4\u201317. https:\/\/doi.org\/10.1016\/j.ymgme.2017.07.010.","journal-title":"Mol Genet Metab"},{"issue":"10","key":"3663_CR11","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/jbmr.3226","volume":"32","author":"JR Shapiro","year":"2017","unstructured":"Shapiro JR, Lewiecki EM. Hypophosphatasia in adults: clinical assessment and treatment considerations. J Bone Miner Res. 2017;32(10):1977\u201380. https:\/\/doi.org\/10.1002\/jbmr.3226.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"3663_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00198-023-06859-8","volume":"35","author":"ML Brandi","year":"2024","unstructured":"Brandi ML, Khan AA, Rush ET, et al. The challenge of hypophosphatasia diagnosis in adults: results from the HPP International Working Group Literature Surveillance. Osteoporos Int. 2024;35(3):439\u201349. https:\/\/doi.org\/10.1007\/s00198-023-06859-8.","journal-title":"Osteoporos Int"},{"issue":"9","key":"3663_CR13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1210\/js.2017-00307","volume":"1","author":"H Remde","year":"2017","unstructured":"Remde H, Cooper MS, Quinkler M. Successful asfotase alfa treatment in an adult dialysis patient with childhood-onset hypophosphatasia. J Endocr Soc. 2017;1(9):1188\u201393. https:\/\/doi.org\/10.1210\/js.2017-00307.","journal-title":"J Endocr Soc"},{"issue":"48","key":"3663_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013210","volume":"97","author":"TQ Freitas","year":"2018","unstructured":"Freitas TQ, Franco AS, Pereira RMR. Improvement of bone microarchitecture parameters after 12 months of treatment with asfotase alfa in adult patient with hypophosphatasia: Case report. Medicine (Baltimore). 2018;97(48): e13210. https:\/\/doi.org\/10.1097\/MD.0000000000013210.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"3663_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/cen.15063","volume":"101","author":"A Schindeler","year":"2024","unstructured":"Schindeler A, Ludwig K, Munns CF. Enzyme replacement therapy for hypophosphatasia-The current paradigm. Clin Endocrinol (Oxf). 2024;101(6):593\u2013601. https:\/\/doi.org\/10.1111\/cen.15063.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"3663_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000531865","volume":"97","author":"GA Martos-Moreno","year":"2024","unstructured":"Martos-Moreno GA, Rockman-Greenberg C, Ozono K, et al. Clinical profiles of children with hypophosphatasia prior to treatment with enzyme replacement therapy: an observational analysis from the global HPP registry. Horm Res Paediatr. 2024;97(3):233\u201342. https:\/\/doi.org\/10.1159\/000531865.","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"3663_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13023-022-02393-8","volume":"17","author":"KM Dahir","year":"2022","unstructured":"Dahir KM, Seefried L, Kishnani PS, et al. Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry. Orphanet J Rare Dis. 2022;17(1):277. https:\/\/doi.org\/10.1186\/s13023-022-02393-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3663_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/jbm4.10052","volume":"2","author":"P Klidaras","year":"2018","unstructured":"Klidaras P, Severt J, Aggers D, Payne J, Miller PD, Ing SW. Fracture healing in two adult patients with hypophosphatasia after asfotase alfa therapy. JBMR Plus. 2018;2(5):304\u20137. https:\/\/doi.org\/10.1002\/jbm4.10052.","journal-title":"JBMR Plus"},{"issue":"8","key":"3663_CR19","doi-asserted-by":"publisher","first-page":"ziae062","DOI":"10.1093\/jbmrpl\/ziae062","volume":"8","author":"KM Dahir","year":"2024","unstructured":"Dahir KM, Ing SW, Deal C, Messali A, Bates T, Rush ET. Improvement in quality of life after asfotase alfa treatment in adults with pediatric-onset hypophosphatasia: data from 5 patient-reported outcome measures. JBMR Plus. 2024;8(8):ziae062. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae062.","journal-title":"JBMR Plus."},{"issue":"12","key":"3663_CR20","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s00198-021-06025-y","volume":"32","author":"L Seefried","year":"2021","unstructured":"Seefried L, Rak D, Petryk A, Genest F. Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa. Osteoporos Int. 2021;32(12):2505\u201313. https:\/\/doi.org\/10.1007\/s00198-021-06025-y.","journal-title":"Osteoporos Int"},{"key":"3663_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.100643","volume":"25","author":"H Nishizawa","year":"2020","unstructured":"Nishizawa H, Sato Y, Ishikawa M, et al. Marked motor function improvement in a 32-year-old woman with childhood-onset hypophosphatasia by asfotase alfa therapy: evaluation based on standardized testing batteries used in Duchenne muscular dystrophy clinical trials. Mol Genet Metab Rep. 2020;25: 100643. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100643.","journal-title":"Mol Genet Metab Rep"},{"key":"3663_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bone.2019.02.025","volume":"122","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, McAlister WH, Mumm S, Bierhals AJ. No vascular calcification on cardiac computed tomography spanning asfotase alfa treatment for an elderly woman with hypophosphatasia. Bone. 2019;122:231\u20136. https:\/\/doi.org\/10.1016\/j.bone.2019.02.025.","journal-title":"Bone"},{"key":"3663_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101163","volume":"16","author":"H Kato","year":"2022","unstructured":"Kato H, Hidaka N, Koga M, et al. Radiological evaluation of pseudofracture after the administration of asfotase alfa in an adult with benign prenatal hypophosphatasia: a case report. Bone Rep. 2022;16: 101163. https:\/\/doi.org\/10.1016\/j.bonr.2021.101163.","journal-title":"Bone Rep"},{"key":"3663_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115794","volume":"143","author":"J Sturznickel","year":"2021","unstructured":"Sturznickel J, Schmidt FN, von Vopelius E, et al. Bone healing and reactivation of remodeling under asfotase alfa therapy in adult patients with pediatric-onset hypophosphatasia. Bone. 2021;143: 115794. https:\/\/doi.org\/10.1016\/j.bone.2020.115794.","journal-title":"Bone"},{"issue":"12","key":"3663_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10842","volume":"7","author":"N Hidaka","year":"2023","unstructured":"Hidaka N, Murata H, Tachikawa K, et al. The effect of asfotase alfa on plasma and urine pyrophosphate levels and pseudofractures in a patient with adult-onset hypophosphatasia. JBMR Plus. 2023;7(12): e10842. https:\/\/doi.org\/10.1002\/jbm4.10842.","journal-title":"JBMR Plus"},{"key":"3663_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bone.2019.05.036","volume":"127","author":"T Rolvien","year":"2019","unstructured":"Rolvien T, Schmidt T, Schmidt FN, et al. Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia. Bone. 2019;127:67\u201374. https:\/\/doi.org\/10.1016\/j.bone.2019.05.036.","journal-title":"Bone"},{"issue":"6","key":"3663_CR27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2169\/internalmedicine.3298-19","volume":"59","author":"H Koyama","year":"2020","unstructured":"Koyama H, Yasuda S, Kakoi S, et al. Effect of asfotase alfa on muscle weakness in a Japanese adult patient of hypophosphatasia with low ALP levels. Intern Med. 2020;59(6):811\u20135. https:\/\/doi.org\/10.2169\/internalmedicine.3298-19.","journal-title":"Intern Med"},{"issue":"6","key":"3663_CR28","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.4158\/ACCR-2019-0143","volume":"5","author":"AL Magdaleno","year":"2019","unstructured":"Magdaleno AL, Singh S, Venkataraman S, Perilli GA, Lee YY. Adult-onset hypophosphatasia: before and after treatment with asfotase alfa. AACE Clin Case Rep Nov-Dec. 2019;5(6):e344\u20138. https:\/\/doi.org\/10.4158\/ACCR-2019-0143.","journal-title":"AACE Clin Case Rep Nov-Dec"},{"issue":"4","key":"3663_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00198-023-06943-z","volume":"35","author":"F Alsarraf","year":"2024","unstructured":"Alsarraf F, Ali DS, Almonaei K, Al-Alwani H, Khan AA, Brandi ML. Hypophosphatasia: presentation and response to asfotase alfa. Osteoporos Int. 2024;35(4):717\u201325. https:\/\/doi.org\/10.1007\/s00198-023-06943-z.","journal-title":"Osteoporos Int"},{"issue":"1","key":"3663_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-024-03048-6","volume":"19","author":"PS Kishnani","year":"2024","unstructured":"Kishnani PS, Martos-Moreno GA, Linglart A, et al. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry. Orphanet J Rare Dis. 2024;19(1):109. https:\/\/doi.org\/10.1186\/s13023-024-03048-6.","journal-title":"Orphanet J Rare Dis"},{"key":"3663_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115664","volume":"142","author":"L Seefried","year":"2021","unstructured":"Seefried L, Kishnani PS, Moseley S, et al. Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Bone. 2021;142: 115664. https:\/\/doi.org\/10.1016\/j.bone.2020.115664.","journal-title":"Bone"},{"issue":"9","key":"3663_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10395","volume":"4","author":"F Genest","year":"2020","unstructured":"Genest F, Rak D, Petryk A, Seefried L. Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia. JBMR Plus. 2020;4(9): e10395. https:\/\/doi.org\/10.1002\/jbm4.10395.","journal-title":"JBMR Plus"},{"key":"3663_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116856","volume":"175","author":"L Seefried","year":"2023","unstructured":"Seefried L, Genest F, Petryk A, Veith M. Effects of asfotase alfa in adults with pediatric-onset hypophosphatasia over 24 months of treatment. Bone. 2023;175: 116856. https:\/\/doi.org\/10.1016\/j.bone.2023.116856.","journal-title":"Bone"},{"key":"3663_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/genes13101880","author":"N Charoenngam","year":"2022","unstructured":"Charoenngam N, Nasr A, Shirvani A, Holick MF. Hereditary metabolic bone diseases: a review of pathogenesis, diagnosis and management. Genes (Basel). 2022. https:\/\/doi.org\/10.3390\/genes13101880.","journal-title":"Genes (Basel)."},{"issue":"10","key":"3663_CR35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/jclinpath-2021-207426","volume":"74","author":"JS Fenn","year":"2021","unstructured":"Fenn JS, Lorde N, Ward JM, Borovickova I. Hypophosphatasia. J Clin Pathol. 2021;74(10):635\u201340. https:\/\/doi.org\/10.1136\/jclinpath-2021-207426.","journal-title":"J Clin Pathol"},{"issue":"3","key":"3663_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00223-019-00626-w","volume":"106","author":"T Michigami","year":"2020","unstructured":"Michigami T, Tachikawa K, Yamazaki M, Kawai M, Kubota T, Ozono K. Hypophosphatasia in Japan: ALPL mutation analysis in 98 unrelated patients. Calcif Tissue Int. 2020;106(3):221\u201331. https:\/\/doi.org\/10.1007\/s00223-019-00626-w.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"3663_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.job.2019.07.003","volume":"61","author":"K Komaru","year":"2019","unstructured":"Komaru K, Ishida-Okumura Y, Numa-Kinjoh N, Hasegawa T, Oda K. Molecular and cellular basis of hypophosphatasia. J Oral Biosci. 2019;61(3):141\u20138. https:\/\/doi.org\/10.1016\/j.job.2019.07.003.","journal-title":"J Oral Biosci"},{"key":"3663_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","volume":"102","author":"MP Whyte","year":"2017","unstructured":"Whyte MP. Hypophosphatasia: an overview For 2017. Bone. 2017;102:15\u201325. https:\/\/doi.org\/10.1016\/j.bone.2017.02.011.","journal-title":"Bone"},{"issue":"Suppl 1","key":"3663_CR39","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.4103\/jpbs.jpbs_662_22","volume":"15","author":"N Jaswanthi","year":"2023","unstructured":"Jaswanthi N, Sindhu R, Nimmy P, et al. Effect of asfotase alfa in the treatment of hypophosphatasia: a systematic review. J Pharm Bioallied Sci. 2023;15(Suppl 1):S101\u20134. https:\/\/doi.org\/10.4103\/jpbs.jpbs_662_22.","journal-title":"J Pharm Bioallied Sci"},{"issue":"4","key":"3663_CR40","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/jbmr.3075","volume":"32","author":"MP Whyte","year":"2017","unstructured":"Whyte MP. Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges. J Bone Miner Res. 2017;32(4):667\u201375. https:\/\/doi.org\/10.1002\/jbmr.3075.","journal-title":"J Bone Miner Res"},{"key":"3663_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116089","volume":"152","author":"RJ Schroth","year":"2021","unstructured":"Schroth RJ, Long C, Lee VHK, Alai-Towfigh H, Rockman-Greenberg C. Dental outcomes for children receiving asfotase alfa for hypophosphatasia. Bone. 2021;152: 116089. https:\/\/doi.org\/10.1016\/j.bone.2021.116089.","journal-title":"Bone"},{"issue":"7","key":"3663_CR42","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1210\/jc.2018-02335","volume":"104","author":"CE Hofmann","year":"2019","unstructured":"Hofmann CE, Harmatz P, Vockley J, et al. Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab. 2019;104(7):2735\u201347. https:\/\/doi.org\/10.1210\/jc.2018-02335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3663_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Simmons JH, Moseley S, et al. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019;7(2):93\u2013105. https:\/\/doi.org\/10.1016\/S2213-8587(18)30307-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3663_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S2213-8587(18)30321-8","volume":"7","author":"R Padidela","year":"2019","unstructured":"Padidela R. Asfotase alfa treatment in perinatal and infantile hypophosphatasia: safe and sustained efficacy. Lancet Diabetes Endocrinol. 2019;7(2):76\u20138. https:\/\/doi.org\/10.1016\/S2213-8587(18)30321-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5\u20136","key":"3663_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10354-020-00736-3","volume":"170","author":"S Simon","year":"2020","unstructured":"Simon S, Resch H. Treatment of hypophosphatasia. Wien Med Wochenschr. 2020;170(5\u20136):112\u20135. https:\/\/doi.org\/10.1007\/s10354-020-00736-3.","journal-title":"Wien Med Wochenschr"},{"key":"3663_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117219","volume":"188","author":"A Shirinezhad","year":"2024","unstructured":"Shirinezhad A, Esmaeili S, Azarboo A, et al. Efficacy and safety of asfotase alfa in patients with hypophosphatasia: a systematic review. Bone. 2024;188: 117219. https:\/\/doi.org\/10.1016\/j.bone.2024.117219.","journal-title":"Bone"},{"issue":"10","key":"3663_CR47","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1093\/jbmr\/zjae128","volume":"39","author":"KM Dahir","year":"2024","unstructured":"Dahir KM, Shannon A, Dunn D, et al. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. J Bone Miner Res. 2024;39(10):1412\u201323. https:\/\/doi.org\/10.1093\/jbmr\/zjae128.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"3663_CR48","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11914-018-0430-3","volume":"16","author":"MR Allen","year":"2018","unstructured":"Allen MR. Recent advances in understanding bisphosphonate effects on bone mechanical properties. Curr Osteoporos Rep. 2018;16(2):198\u2013204. https:\/\/doi.org\/10.1007\/s11914-018-0430-3.","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"3663_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010009","volume":"18","author":"F Xiao","year":"2022","unstructured":"Xiao F, Zhou Z, Song X, et al. Dissecting mutational allosteric effects in alkaline phosphatases associated with different Hypophosphatasia phenotypes: an integrative computational investigation. PLoS Comput Biol. 2022;18(3): e1010009. https:\/\/doi.org\/10.1371\/journal.pcbi.1010009.","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"3663_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ymgme.2019.05.014","volume":"127","author":"C Nakano","year":"2019","unstructured":"Nakano C, Kitabatake Y, Takeyari S, et al. Genetic correction of induced pluripotent stem cells mediated by transcription activator-like effector nucleases targeting ALPL recovers enzyme activity and calcification in vitro. Mol Genet Metab. 2019;127(2):158\u201365. https:\/\/doi.org\/10.1016\/j.ymgme.2019.05.014.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3663_CR51","doi-asserted-by":"publisher","first-page":"e10709","DOI":"10.1002\/jbm4.10709","volume":"7","author":"F Amadeu de Oliveira","year":"2023","unstructured":"Amadeu de Oliveira F, Mohamed FF, Kinoshita Y, et al. Gene therapy using recombinant AAV Type 8 vector encoding TNAP-D(10) improves the skeletal phenotypes in murine models of osteomalacia. JBMR Plus. 2023;7(1):e10709. https:\/\/doi.org\/10.1002\/jbm4.10709.","journal-title":"JBMR Plus."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03663-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03663-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03663-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T09:45:46Z","timestamp":1744019146000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03663-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,6]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3663"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03663-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,6]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the scientific ethics committee of PUMCH. The patient signed informed consent before participating in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study contains anonymized patient data. No direct patient identifiers have been provided in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}